CXCL12 and cancer: MSCs and FBs ease the pathogenetic interaction between PCs and BMME via the excretion of CXCL12 (CXCR4 ligand, expressed on ECs and malignant PCs), which is relevant in the “cancer immunoediting” process [10,47].